Rationale: Women with hormone receptor-positive, HER2-negative, node-negative breast cancer with intermediate OncotypeDX scores were randomized to either endocrine therapy alone or chemoendocrine therapy. Intermediate scores were 11-25 with an estimated 10-20% risk of distant recurrence at 10 years. Excellent outcomes among the low risk group have already been reported, but this intermediate group represents the vast majority of patients (67%). The primary outcome is non-inferiority of invasive disease-free survival (DFS) with endocrine therapy alone. Betting line: DFS will be higher than expected across the board, with endocrine therapy being non-inferior pending no statistical derailments with too few events. | ASCO plenary 2018


Popular Posts